Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 .
Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ). mylan stock buy or sell
Management expects roughly 2% total revenue growth and strong free cash flow exceeding $2.5 billion . Discounted Cash Flow (DCF) models suggest the stock
AI responses may include mistakes. For financial advice, consult a professional. Learn more which may appeal to income-focused investors.
The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings.
Viatris offers a solid dividend yield of approximately 3.24% , which may appeal to income-focused investors.